Dysregulation in the activity of FoxO1 has been implicated in the pathophysiology of diabetic cardiomyopathy (DCM) (Battiprolu et al., 2012; Kandula et al., 2016), along with ischemic and cardiac hypertrophy (Ni et al., 2006), which suggests that FoxO1 is a therapeutic target for these myocardial diseases. The gene discussed is FOXO1; the disease is familial dilated cardiomyopathy.